Is proteinuria a plausible target of therapy?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Microalbuminuria is an independent marker of cardiovascular risk, irrespective of kidney disease. Recent pharmacologic interventions have resulted in a significant delay and even an arrest in the progression of microalbuminuria to macroalbuminuria or to chronic kidney disease. Focus should be placed on agents that not only lower blood pressure but also improve albuminuria levels. Current guidelines recommend that hypertensive patients with renal disease should be started on agents that block the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The use of three to four different agents is frequently necessary to reach the guideline goal blood pressure of 130/80 mm Hg.
- Manjunath G, Tighiouart H, Ibrahim H, et al.: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003, 41:47–55. CrossRef
- Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572. CrossRef
- US Renal Data System: USRDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April, 1999.
- Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. The National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661.
- American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002, 25(Supp)1:S1-S147. CrossRef
- Kidney Disease Outcome Quality Initiative: Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S246. CrossRef
- Eknoyan G, Hostetter T, Bakris GL, et al.: Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis 2003, 42:617–622. CrossRef
- Mogensen CE, Vestbo E, Poulsen PL, et al.: Microalbuminuria and potential confounders: a review and some observations on variability of urinary albumin excretion. Diabetes Care 1995, 18:572–581.
- Garg JP and Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7:35–43. CrossRef
- Russo LM, Bakris GL, Comper WD: Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002, 39:899–919. CrossRef
- Bianchi S, Bigazzi R, Campese VM: Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999, 34:973–995.
- Sibley SD, Hokanson JE, Steffes MW, et al.: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999, 22:1165–1170. CrossRef
- Gerstein HC, Mann JF, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426. CrossRef
- Roest M, Banga JD, Janssen WM, et al.: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001, 103:3057–3061.
- Stuveling EM, Bakker SJL, Hillege HL, et al.: C-reactive protein modifies the relation between blood pressure and microalbuminuria. Hypertension 2004, 43:791–796. This study demonstrates the direct relationship between microalbuminuria and CRP. CrossRef
- Hart PD, Bakris GL: Managing hypertension in the diabetic patient. In Hot Topics in Hypertension. Edited by Egan BM, Basile JN, Lackland DT. Philadelphia: Hanley and Belfus; 2004:249–252.
- Miettinen H, Haffner SM, Lehto S, et al.: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996, 27:2033–2039.
- Jafar TH, Stark PC, Schmid CH, et al.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131–1140. CrossRef
- Ferder L, Daccordi H, Martello M, et al.: Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992, 19(2 Suppl):II237-II242.
- Garg J, Bakris GL: Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther 2002, 16:503–510. CrossRef
- Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993–2000.
- Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925–1930. CrossRef
- Braam B, Koomans HA: Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens 1996, 5:89–96. CrossRef
- Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939–945. CrossRef
- Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The Collaborative Study Group. N Engl J Med 2001, 345:852–860. The first of the two large studies that accounted for ARB recommendation in type 2 diabetes. In this study, the superiority of irbesartan over amlodipine was also shown.
- Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995–1003. CrossRef
- Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type-2 diabetes. N Engl J Med 2003, 348:383–393. CrossRef
- The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Gruppo Italiano di Studi Epidemiologici in Nefrologia. Lancet 1997, 349:1857–1863. CrossRef
- Klag MJ, Whelton PK, Randall BL, et al.: End stage renal disease in African-American and white men. JAMA 1997, 227:1293–1298. CrossRef
- Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431. Although most of the individuals had microalbuminuria, a lower BP was not found to be of benefit. It is clear, however, that black patients should not be denied RAS blockers, as they markedly reduce the risk of renal disease progression when appropriately used with other agents to achieve goal BP. This paper is the first to provide guidance for what level of BP a physician should achieve in someone who has high levels of proteinuria and has kidney disease. CrossRef
- Weinberg MS, Cord R, Weinberg AJ, Zappe DH: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone Syst 2001, 2(Suppl 1):S196-S198.
- Peters H, Ritz E: Dosing angiotensin II blockers—beyond blood pressure. Nephrol Dial Transplant 1999, 14:2568–2570. CrossRef
- Bakris GL, Slataper R, Vicknair N, Sadler R: ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994, 8:2–6. CrossRef
- Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874–1880. This study evaluated the antiproteinuric effects of adding high-dose ARB therapy (irbesartan 300 mg/d) to pre-existing maximal ACEinhibitor therapy. CrossRef
- Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124. Data from this study suggest that the combination of an ACE inhibitor with an ARB should only be for further reduction in proteinuria among those with high levels of protein excretion, and not for achievement of BP goals. CrossRef
- McMurray JJV, Östergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771. CrossRef
- Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. CrossRef
- Buter H, Hemmelder MH, Navis G, et al.: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998, 13:1682–1685. CrossRef
- Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886–1892. CrossRef
- Anonymous: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. The ALLHAT study was the largest ever completed, with more than 42,000 participants. There were no differences (between chlorthalidone, amlodipine, and lisinopril) in the 6-year rate of the primary outcome, defined as fatal CHD or nonfatal myocardial infarction combined. However, from a renal standpoint, proteinuria was not measured.
- Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF: Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 1998, 53:1559–1573. CrossRef
- Hayashi K, Ozawa Y, Fujiwara K, et al.: Role of actions of calcium antagonists on efferent arterioles—with special references to glomerular hypertension. Am J Nephrol 2003, 23:229–244. This is an in-depth review that covers the intrarenal hemodynamic changes of calcium antagonists in animal models and in humans. CrossRef
- Bakris GL, Griffin KA, Picken MM, Bidani AK: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997, 15:1181–1185. CrossRef
- The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990, 66:779–785. CrossRef
- Black HR, Elliott WJ, Grandits G, et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073–2082. CrossRef
- Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163:1555–1565. Patients with the highest baseline pulse pressure have the most risk for nephropathy progression but also gather the greatest risk reduction if SBP is lowered to less than 140 mm Hg. Also supports previous animal and human studies finding that the use of dihydropyridine CAs in the presence of RAS blockers does not abrogate the benefit of slowing kidney disease progression or increasing proteinuria. CrossRef
- Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728. CrossRef
- Otterstad JE, Ford I: The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction: How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002, 4:501–506. CrossRef
- Thomas MC, Cooper ME, Shahinfar S, Brenner BM: Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. Kidney Int 2003, 63:1577–1579. CrossRef
- Is proteinuria a plausible target of therapy?
Current Hypertension Reports
Volume 6, Issue 3 , pp 177-181
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors